Breaking News from the ADA 76th Scientific Sessions

Learning Objectives

  • Discuss the results of recent cardiovascular trials
  • Discuss some of the proposed mechanisms through which cardiovascular and renal benefits with newer antihyperglycemic agents in diabetes
  • Evaluate the role of combination therapy in the management of hyperglycemia
  • Facilitate knowledge translation of recent evidence into clinical practice

Agenda

Click to see videos in chapters

00:00:00 Opening Remarks
Dr. Lawrence A. Leiter
00:04:20 Chapter 1
The LEADER Trial
Dr. Lawrence A. Leiter
What Are the Potential Mechanisms of Benefit in the LEADER Trial?
Dr. Subodh Verma
Expert Panel Discussion
00:37:37 Chapter 2
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Dr. David Fitchett
A Potpourri of Mechanistic and Translational News on DPP-4 Inhibitors and SGLT2 Inhibitors
Dr. Subodh Verma
Expert Panel Discussion
01:05:36 Chapter 3
New Data on Novel Combinations of GLP1RA/Insulin Combinations
Dr. Stewart Harris
Expert Panel Discussion
01:34:35 Closing Remarks
Dr. Lawrence A. Leiter

Faculty

Lawrence A. Leiter
MD, FRCPC, FACP, FACE, FAHA
Endocrinologist, St. Michael’s Hospital
Professor of Medicine and Nutritional Sciences, University of Toronto

Subodh Verma
MD, PhD, FRCSC, FAHA
Cardiac Surgeon, St. Michael’s Hospital
Professor of Surgery and Pharmacology, University of Toronto

Stewart B Harris
CM, MD, MPH, FCFP, FACPM
Professor, CDA
Chair in Diabetes Management Ian McWhinney Chair of Family Medicine Studies, Centre for Studies in Family Medicine, Schulich School of Medicine & Dentistry, Western University

David H Fitchett
MD, FRCC, FACC, FESC
Division of Cardiology, St. Michael’s Hospital
Associate Professor of Medicine, University of Toronto

Video Information
  • Credit:No Credit Available
  • Post Date:September 19, 2016
  • Expiry Date:N/A

Related Videos